Search
Cholesterol
go.drugbank.com/drugs/DB04540ApprovedInvestigationalWithdrawnThe principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
Categories: P-glycoprotein inhibitorsCapravirine
go.drugbank.com/drugs/DB08502InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesChloramphenicol succinate
go.drugbank.com/drugs/DB07565ApprovedChloramphenicol succinate is an ester prodrug of chloramphenicol. Chloramphenicol is a bacteriostatic antibiotic. Use of chloramphenicol succinate and chloramphenicol has decreased due to the risk of potentially fatal blood dyscrasias. C...
Categories: P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic IndexLinafexor
go.drugbank.com/drugs/DB18031InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGunagratinib
go.drugbank.com/drugs/DB18191ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigationalLonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone (somatropin) indicated for the treatment of children 1 year and older, weighing at least 11.5 kg, with growth failure due to ...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InducersLoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalRelapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to t...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesMiricorilant
go.drugbank.com/drugs/DB16234InvestigationalMiricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesOlutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigationalOlutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with ...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsTL-895
go.drugbank.com/drugs/DB16471InvestigationalTL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. TL-895 is under investigation in several clinical trials for its safety and ef...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates